Table 1

Patient demographics

Cohort
GPi
Odekerken et al.3
STN
Horn et al.5
Age, years60 (±6)60 (±8)
n (female)28 (10)94 (29)
UPDRS-III baseline OFF43 (±14)43 (±14)
UPDRS-III ON34 (±13)22 (±10)
Improvement, %13 (±43)47 (±23)
Improvement absolute9 (±17)21 (±13)
LEDD baseline13251241
LEDD ON1091522
LEDD reduction %15 (±23)57 (±34)
Postoperative imaging MR/CT0/2845/49
Cohort
GPi
Odekerken et al.3
STN
Horn et al.5
Age, years60 (±6)60 (±8)
n (female)28 (10)94 (29)
UPDRS-III baseline OFF43 (±14)43 (±14)
UPDRS-III ON34 (±13)22 (±10)
Improvement, %13 (±43)47 (±23)
Improvement absolute9 (±17)21 (±13)
LEDD baseline13251241
LEDD ON1091522
LEDD reduction %15 (±23)57 (±34)
Postoperative imaging MR/CT0/2845/49

LEDD = levodopa equivalent daily dose.

Table 1

Patient demographics

Cohort
GPi
Odekerken et al.3
STN
Horn et al.5
Age, years60 (±6)60 (±8)
n (female)28 (10)94 (29)
UPDRS-III baseline OFF43 (±14)43 (±14)
UPDRS-III ON34 (±13)22 (±10)
Improvement, %13 (±43)47 (±23)
Improvement absolute9 (±17)21 (±13)
LEDD baseline13251241
LEDD ON1091522
LEDD reduction %15 (±23)57 (±34)
Postoperative imaging MR/CT0/2845/49
Cohort
GPi
Odekerken et al.3
STN
Horn et al.5
Age, years60 (±6)60 (±8)
n (female)28 (10)94 (29)
UPDRS-III baseline OFF43 (±14)43 (±14)
UPDRS-III ON34 (±13)22 (±10)
Improvement, %13 (±43)47 (±23)
Improvement absolute9 (±17)21 (±13)
LEDD baseline13251241
LEDD ON1091522
LEDD reduction %15 (±23)57 (±34)
Postoperative imaging MR/CT0/2845/49

LEDD = levodopa equivalent daily dose.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close